Resverlogix and Zenith combined have thousands of compounds. Not all are the same. Different selectivities for BD1 vs BD2, for the different BET bromodomain proteins (BRD2, BRD3, BRD4, etc.), different modes of inhibition (competitive vs. covalent/suicide). Additionally, some inhibitors bind both bromodomains very tightly, others have a mild preference for one vs. the other, others have a strong preference. Furthermore, slight differences in how the inhibitor fits into a binding pocket can lead to big differences in the structure and transcriptional activity. 

Long story short, there is enormous potential in those compound libraries, regardless of whether it is currently a clinical or pre-clinical compound. Keep in mind that both Resverlogix and Zenith have done an enormous amount of cell and animal work to evaluate many of these other compounds. Just because the company's haven't presented or published about them doesn't mean that the companies don't know their properties and potential.

BDAZ